Digest Network Come funziona
Network
/
Società
Fo
Non verificato

Fore Biotherapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

18 comunicati stampa

Guarda tutti i comunicati
01/04/2026
Industria
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
04/11/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
13/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
FORE Biotherapeutics to Host Virtual Key Opinion Leader Roundtable Discussion on Plixorafenib’s Potential to Disrupt the BRAF Market to Benefit Patients
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
24/09/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
12/09/2025
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Industria
FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
27/08/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Fiere
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
27/05/2025
Eventi
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
22/05/2025
Industria
Eventi
Finanza
Igiene alimentare
Biotecnologia
Medicina - Varie
Associazioni/Professionisti
Salute
Farmaceutica
Oncologia
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
30/04/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
FORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0
25/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients
Fonte
Fore Biotherapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0